Surging in public awareness since the global COVID-19 pandemic and with cross-sector growth of artificial intelligence (AI) across industries, Astell Scientific predicts that 2025 will be a groundbreaking year for the field.
With more than 140 years’ experience producing autoclaves for microbiological research laboratories, the company predicts that 2025 will be a year of significant change.
Multiple de novo protein therapeutics, designed entirely by AI, are expected to enter human clinical trials, and could revolutionise antimicrobial drug development. Combined with advanced data analysis tools, AI will also be used to accelerate drug discovery and predictive modelling in microbiology research. Such medicine will become increasingly precise, with personalised treatments derived from genomic and proteomic insights enabling more targeted approaches to combating microbial infections.
The company predicts that such precision will also be applied to technologies such as CRISPR, enabling targeted solutions for microbial diseases and genetic conditions.
Another prediction is that long-read sequencing platforms will be widely adopted, offering superior coverage and deeper data insights for microbiological research. Growth is also expected in the immunology and inflammation (I&I) sector, driven by a deeper understanding of immune system mechanisms and the development of targeted therapies for microbial infections.
The integrations of genomics, proteomics, metabolomics, and transcriptomics will enable scientists to gain a holistic understanding of microbial disease mechanisms. And the star of the show is predicted by Astell to be metabolomics – uncovering critical molecules and reshaping the therapeutic landscape of microbiology.
Astell’s Director of Sales and Marketing, Paul Birchmore, shared his thoughts: "The field of microbiology is advancing at an unprecedented pace. At Astell, we are proud to support pioneering developments that enhance and prolong lives while contributing to the cumulative knowledge of humankind. By providing autoclaves that function so effectively they almost go unnoticed in the lab, we aim to simplify the lives of those driving breakthroughs every day. We look forward to continuing our partnership with researchers in 2025 and well into the future."
